Kalohexis' once daily oral 710GO activates the melanocortin 3 and melanocortin 4 brain receptors at the same time, in a design the company says avoids the cardiovascular and efficacy ceilings of earlier single receptor melanocortin obesity drugs, with the only published data so…
At the Endocrine Society's ENDO 2026 meeting in Chicago on June 15, 2026, Kalohexis Inc. is presenting preclinical data on 710GO, a once-daily oral obesity pill that activates two related brain receptors (melanocortin-3, or MC3R, and melanocortin-4, or MC4R) at the same time. A Phase 1 trial in general obesity is underway, but no human efficacy or safety data exist yet.
Kalohexis is positioning 710GO against the failure modes of earlier melanocortin-pathway drugs, including selective MC4R-only agonists in the setmelanotide class. The company's argument is that the earlier programs ran into two walls: cardiovascular signals (heart rate, blood pressure, and QTc changes) at high doses, and an efficacy ceiling that did not compete with the GLP-1 class. Hitting MC3R alongside MC4R, the company says, is what is supposed to avoid that ceiling.
In obese nonhuman primates, the company reports 710GO drove 11.8% weight loss versus vehicle over 15 weeks, with limited rebound after treatment stopped and relative preservation of lean mass rather than the muscle loss that has dogged high-dose GLP-1 therapy in some studies. No heart-rate, blood-pressure, or QTc signal appeared at oral doses up to 60 mg/kg. The data are preclinical, in a primate model, and have not been replicated by an independent group.
MC4R agonism is the established satiety signal in this pathway. The novelty is MC3R. By Kalohexis' framing, MC3R contributes energy-expenditure and metabolic-rate effects, and dual activation is what is meant to keep cardiovascular signals at bay. Primate data are the first place the hypothesis gets tested in any species, and a Phase 1 human trial is the first place it gets tested in patients.
The framing comes from a company press release tied to a sponsored conference presentation, and the presenting author, Jillian L. Seiler, Ph.D., is Lead Scientist at Endevica Bio, the parent organization, not at Kalohexis itself. Kalohexis was spun out of Endevica Bio in March 2026, with headquarters in Northbrook, Illinois. No independent endocrinologist or obesity pharmacologist has publicly commented on the primate-to-human translation; that is the next input the field will need.
The watch items are concrete. A clean Phase 1 read on cardiovascular and central-nervous-system safety in healthy volunteers would de-risk the design. A Phase 2 proof-of-concept on body composition, fat loss versus lean mass, is what would actually validate the lean-mass-sparing claim against the GLP-1 RA class. And whether 710GO can hold its efficacy as a once-daily oral, without the GI tolerability problems that have made some oral peptides difficult, is the other open variable.